17.06 USD
+0.17 (+1.01%)
17.06 USD
0 (0%)
Overall SGRY gets a fundamental rating of 4 out of 10. We evaluated SGRY against 101 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of SGRY while its profitability can be described as average. SGRY is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SGRY was profitable.
In the past year SGRY had a positive cash flow from operations.
SGRY had negative earnings in each of the past 5 years.
Each year in the past 5 years SGRY had a positive operating cash flow.
1.2 Ratios
SGRY has a Return On Assets (-2.27%) which is comparable to the rest of the industry.
SGRY has a Return On Equity (-10.32%) which is in line with its industry peers.
SGRY's Return On Invested Capital of 5.18% is in line compared to the rest of the industry. SGRY outperforms 58.42% of its industry peers.
SGRY had an Average Return On Invested Capital over the past 3 years of 5.03%. This is below the industry average of 9.27%.
The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.18%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -10.32% | ||
| ROIC | 5.18% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
SGRY's Operating Margin of 14.96% is amongst the best of the industry. SGRY outperforms 89.11% of its industry peers.
SGRY's Operating Margin has been stable in the last couple of years.
The Gross Margin of SGRY (26.51%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.51% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SGRY is destroying value.
SGRY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SGRY has been increased compared to 5 years ago.
SGRY has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.76, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
SGRY has a worse Altman-Z score (0.76) than 74.26% of its industry peers.
The Debt to FCF ratio of SGRY is 20.39, which is on the high side as it means it would take SGRY, 20.39 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 20.39, SGRY is in line with its industry, outperforming 40.59% of the companies in the same industry.
A Debt/Equity ratio of 1.98 is on the high side and indicates that SGRY has dependencies on debt financing.
SGRY's Debt to Equity ratio of 1.98 is on the low side compared to the rest of the industry. SGRY is outperformed by 73.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.98 | ||
| Debt/FCF | 20.39 | ||
| Altman-Z | 0.76 |
ROIC/WACC0.58
WACC8.86%
2.3 Liquidity
A Current Ratio of 1.93 indicates that SGRY should not have too much problems paying its short term obligations.
SGRY has a Current ratio of 1.93. This is in the better half of the industry: SGRY outperforms 79.21% of its industry peers.
A Quick Ratio of 1.78 indicates that SGRY should not have too much problems paying its short term obligations.
SGRY has a Quick ratio of 1.78. This is in the better half of the industry: SGRY outperforms 71.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
The Revenue has been growing by 11.20% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
Based on estimates for the next years, SGRY will show a very strong growth in Earnings Per Share. The EPS will grow by 21.60% on average per year.
Based on estimates for the next years, SGRY will show a quite strong growth in Revenue. The Revenue will grow by 10.15% on average per year.
EPS Next Y-6.74%
EPS Next 2Y6.36%
EPS Next 3Y10.25%
EPS Next 5Y21.6%
Revenue Next Year8.89%
Revenue Next 2Y9.24%
Revenue Next 3Y9.12%
Revenue Next 5Y10.15%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.87, SGRY is valued on the expensive side.
SGRY's Price/Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 66.34% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.15. SGRY is around the same levels.
With a Price/Forward Earnings ratio of 16.04, SGRY is valued correctly.
Based on the Price/Forward Earnings ratio, SGRY is valued a bit cheaper than 76.24% of the companies in the same industry.
SGRY is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.87 | ||
| Fwd PE | 16.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 79.21% of the companies listed in the same industry.
80.20% of the companies in the same industry are more expensive than SGRY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.48 | ||
| EV/EBITDA | 8.55 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.36%
EPS Next 3Y10.25%
5. Dividend
5.1 Amount
SGRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.06
+0.17 (+1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners75.05%
Inst Owner Change5.61%
Ins Owners1.12%
Ins Owner Change-0.09%
Market Cap2.19B
Revenue(TTM)3.11B
Net Income(TTM)-180.40M
Analysts81.11
Price Target28.87 (69.23%)
Short Float %17.88%
Short Ratio7.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.1%
Min EPS beat(2)-24.34%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.82%
Min EPS beat(4)-26.04%
Max EPS beat(4)24.15%
EPS beat(8)6
Avg EPS beat(8)7.1%
EPS beat(12)9
Avg EPS beat(12)175.54%
EPS beat(16)11
Avg EPS beat(16)112.22%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.58%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)-0.88%
PT rev (1m)-9.29%
PT rev (3m)-9.77%
EPS NQ rev (1m)0.24%
EPS NQ rev (3m)-10.3%
EPS NY rev (1m)-1.43%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.87 | ||
| Fwd PE | 16.04 | ||
| P/S | 0.68 | ||
| P/FCF | 12.48 | ||
| P/OCF | 8.29 | ||
| P/B | 1.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.55 |
EPS(TTM)0.78
EY4.57%
EPS(NY)1.06
Fwd EY6.23%
FCF(TTM)1.37
FCFY8.01%
OCF(TTM)2.06
OCFY12.07%
SpS25.25
BVpS13.64
TBVpS-26.45
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -10.32% | ||
| ROCE | 6.56% | ||
| ROIC | 5.18% | ||
| ROICexc | 5.36% | ||
| ROICexgc | 19.21% | ||
| OM | 14.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.51% | ||
| FCFM | 5.42% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.98 | ||
| Debt/FCF | 20.39 | ||
| Debt/EBITDA | 5.37 | ||
| Cap/Depr | 55.13% | ||
| Cap/Sales | 2.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 40.92% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 0.76 |
F-Score4
WACC8.86%
ROIC/WACC0.58
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-6.74%
EPS Next 2Y6.36%
EPS Next 3Y10.25%
EPS Next 5Y21.6%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year8.89%
Revenue Next 2Y9.24%
Revenue Next 3Y9.12%
Revenue Next 5Y10.15%
EBIT growth 1Y8.03%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year49.11%
EBIT Next 3Y22.59%
EBIT Next 5YN/A
FCF growth 1Y138.83%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y61.41%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 4 / 10 to SGRY.
Can you provide the valuation status for SURGERY PARTNERS INC?
ChartMill assigns a valuation rating of 5 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for SGRY stock?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 21.87 and the Price/Book (PB) ratio is 1.25.
Is the dividend of SURGERY PARTNERS INC sustainable?
The dividend rating of SURGERY PARTNERS INC (SGRY) is 0 / 10 and the dividend payout ratio is 0%.